Description
Created On: 2020-07-15
Record Count: 5
Primary Industries
- Drugs
- Disease
- Delivery
- Therapeutic
- Dialysis
- Diabetes Treatment
- Kidneys
- Nutraceutical
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 263341
TPN TRIFERIC® is a total parenteral nutrituional (TPN) product incorporating SFP (soluble ferric pyrophosphate) including those for replacement/maintenance of iron, management of iron disorders, preventing and treating medical conditions such as absolute or functional iron deficiency and iron deficiency anemia in any and all indications where SFP, delivered by TPN, may be useful.
Licensor owns certain patent rights, trade secrets, know how, and other proprietary information and technology related to the use of soluble ferric pyrophosphate (“SFPâ€) including for use in management of iron disorders including preventing and treating medical conditions such as absolute or functional iron deficiency and iron deficiency anemia.
Iron deficiency anemia is a common type of anemia — a condition in which blood lacks adequate healthy red blood cells. Red blood cells carry oxygen to the body's tissues.
Licensor Patent Rights means the patent applications and patents listed; and continuing applications thereof including divisions, substitutions, extensions and continuation-in-part applications; any patents issuing on said applications or continuing applications including reissues and re-examined applications and any corresponding foreign patents or applications; as well as any patent term extensions or adjustments thereof; to the extent the above covers or applies to Licensed Products.
Patent:
9,161,951 – United States – Issue Date 10/20/2015 – Parenteral nutrition composition containing iron
Licensed Products means all compositions of matter, formulations, articles of manufacture, materials, and products using, including, comprising or incorporating SFP or any specific species thereof, including generics, in the licensed field of use that incorporate the Licensor Technology.
Licensor Technology means subject matter disclosed, described or claimed in Licensor Patent Rights and Licensor Know How that has been documented prior to the effective date.
Triferic is a revolutionary iron therapy that replaces iron and maintains hemoglobin without increasing iron stores, and Triferic is the only FDA approved product indicated to replace iron and maintain hemoglobin concentration in adult HDD-CKD hemodialysis patients.
IPSCIO Record ID: 263340
Licensor owns certain patent rights, trade secrets, know how, and other proprietary information and technology related to the use of soluble ferric pyrophosphate (“SFPâ€) including for use in management of iron disorders including preventing and treating medical conditions such as absolute or functional iron deficiency and iron deficiency anemia.
Licensed Products means all compositions of matter, formulations, articles of manufacture, materials, and products using, including, comprising or incorporating SFP or any specific species thereof, including generics, in the licensed field of use that incorporate the Licensor Technology.
Licensor Patent Rights means the patent applications and patents listed; and continuing applications thereof including divisions, substitutions, extensions and continuation-in-part applications; any patents issuing on said applications or continuing applications including reissues and re-examined applications and any corresponding foreign patents or applications; as well as any patent term extensions or adjustments thereof; to the extent the above covers or applies to Licensed Products.
6,779,468 – United States – Issued 08/24/2004 – Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients
61/759531 – United States – Application
14/765111 – United States – Application
14/765111 – United States – Application
Licensor Technology means subject matter disclosed, described or claimed in Licensor Patent Rights and Licensor Know How that has been documented prior to the effective date.
IPSCIO Record ID: 263343
This Amendment is to ratify existing Sub-Licenses and Supply Agreements.
The Parties further agree to complete a subsequent Amendment according to the binding terms and consistent with the Commercialization and Technology License Agreement – IV Triferic (IV License) executed on even date to the extent that it would not conflict with this Amendment.
Triferic® is a proprietary iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. The Company has developed two presentations of Triferic that are added to the dialysate, or Dialysate Triferic. Triferic is the first and only FDA-approved iron replacement product indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD). It is believed Triferic addresses an important unmet need in the treatment of ongoing iron losses and anemia in ESRD patients. Triferics unique mode-of-action distinguishes it from conventional I.V. iron products because Triferic donates iron to transferrin, immediately, and completely, as soon as it enters the blood. The iron bound to transferrin is transported to the bone marrow to make hemoglobin. Triferic delivers approximately 5 & 7 mg of iron with every hemodialysis. Triferic is the first and only FDA-approved iron replacement product indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD). We believe Triferic addresses an important unmet need in the treatment of ongoing iron losses and anemia in ESRD patients. Triferic s unique mode-of-action distinguishes it from conventional I.V. iron products because Triferic donates iron to transferrin, immediately, and completely, as soon as it enters the blood. The iron bound to transferrin is transported to the bone marrow to make hemoglobin. Triferic delivers approximately 5 & 7 mg of iron with every hemodialysis.
IPSCIO Record ID: 286043
Patent Application # U.S.S.N. 60/073,603 entitled 'N,N-Bis(2-Hydroxybenzyl) Ethylenediamine-N,N-Diacetic Acid in Iron Chelating Theraphy'.
Agreement Compounds means the monosodium salt of N,N-bis (2-hydroxybenzyl) ethylenediamine-N,N diacetic acid (hereinafter 'NaHBED' or 'HBED'), or any other mono-cation salt of HBED.
Licensed Products means any product or part thereof which:
(a) is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Licensed Patents in the country in which any Licensed Products are made, used or sold;
(b) is manufactured by using a process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Licensed Patents in the country in which any Licensed Process is used or in which such product or part thereof is used or sold;
(c) is derived from Licensed Patents, Know-How and/or trade secrets related to or described in the Licensed Patents; (d) is sold, manufactured or used in any country under this Agreement; and/or
(e) contains Agreement Compounds in final packaged form suitable for distribution to non-affiliated customers and bears Licensees or Licensees Affiliates typical trade dress.
Intellectual property relates to develop and market a proprietary iron chelator. Iron chelation therapy is the removal of excess iron from the body with special drugs.
Thalassemia is a blood disorder passed down through families (inherited) in which the body makes an abnormal form or inadequate amount of hemoglobin. Hemoglobin is the protein in red blood cells that carries oxygen. The disorder results in large numbers of red blood cells being destroyed, which leads to anemia.
Sickle cell anemia is an inherited form of anemia — a condition in which there aren't enough healthy red blood cells to carry adequate oxygen throughout your body.
Myelodysplastic syndromes (MDS) are a group of cancers in which immature blood cells in the bone marrow do not mature and therefore do not become healthy blood cells.
IPSCIO Record ID: 7486
FerroHeme has been granted Natural Product Number 80001571 by Health Canada, for the prevention and treatment of anemia and iron deficiencies, and contains a novel, proprietary hemoglobin-protein complex that is biologically identical to the iron and oxygen carrying hemoglobin in the human body. Unlike non-heme iron supplements, such as ferrous sulphate, ferrous gluconate and other synthetic iron supplements that are predominantly sold and used by consumers globally, FerroHeme has a superior absorption profile, thus allowing full absorption and bio-availability of iron to humans, without the high incidence of gastrointestinal side effects, such as constipation, nausea and abdominal pain and, most importantly, the dangerous risks of cellular oxidative damage, iron toxicity and hemochromatosis. It also prevents sudden boosts of iron which can overwhelm the body's ability to manage the mineral.
